clinical trial · NCT00311844
A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)
Organon and Co·phase4·completed·n = 41
Conjunctivitis, Allergicdesloratadine
brief summary
This study was a double-blind, placebo-controlled, cross-over, single-center study of desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal allergic rhinoconjunctivitis. This study was performed to examine the effects of desloratadine compared with placebo, on the signs and symptoms of allergic conjunctivitis induced by direct conjunctival challenges with a previously identified sensitizing antigen, in the eyes of a subject known to be sensitive to the antigen.
started
Mar 1, 2005
primary completion
May 28, 2005
completion
May 28, 2005
last updated
Aug 15, 2024
official title
A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol